Home Tags ADCT-301

Tag: ADCT-301

Featured Image: View of Lugano old town with mountains in the background, Switzerland. Courtesy: © 2017. Fotolia. Used with permission.

Pyrrolobenzodiazepine-based ADCs Demonstrate Potential in R/R Lymphomas

The International Conference on Malignant Lymphoma (ICML) has, since its first edition in 1981, become one of the must-attend conferences for the scientific community...

First Patient Dosed in Phase Ib Clinical Trial of Camidanlumab Tesirine...

A first patient has been dosed in Phase Ib clinical trial of camidanlumab tesirine, also know ADCT-301, a proprietary antibody-drug conjugate or ADC being...

Interim Phase I Data from Camidanlumab Tesirine (ADCT-301) Shows Encouraging Preliminary...

Clinical data from two ongoing Phase I clinical trials evaluating camidanlumab tesirine, also known as ADCT-301* or "Cami-T", in important subtypes of lymphoma and...

Interim Data Shows Favorable Tolerability and Efficacy Results of ADCT-301 in...

Interim results from an ongoing Phase I, open label, dose-escalating study evaluating ADCT-301, being developed by ADC Therapeutics for the treatment of relapsed or refractory...

Successful Funding Round Expected to Accelerate ADC Therapeutics’ Clinical Development

Swiss Biotech company ADC Therapeutics, an oncology drug discovery and development company specializing in the development of proprietary antibody-drug conjugates or ADCs for the treatment...

First Patient Dosed in Phase I Trial of ADCT-301 Trial

Earlier this month ADC Therapeutics, a Swiss-based oncology drug development company, dosed the first patient in a Phase I trial to evaluate ADCT-301, also...

ADC Therapeutics Raises US$ 80 million to Advance ADC Pipeline

ADC Therapeutics, an oncology drug discovery and development company headquartered in Lausanne, Switzerland and London, UK, that specializes in the development of proprietary Antibody...

ADCT-301 – A Novel Antibody-drug Conjugate Against Lymphomas – Moves Into...

ADC Therapeutics Sarl (Epalinges, Switzerland), a company involved in the development of antibody-drug conjugates against solid and hematological cancers, has filed an Investigational New Drug application or...

DOWNLOAD